FWA
ATXS

Freedom Wealth Alliance’s Astria Therapeutics ATXS Stock Holding History

Freedom Wealth Alliance’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,150
Closed -$17.1K – 100
2022
Q4 		$17.1K Buy
+1,150
New +$11.9K 0.02% 222

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Freedom Wealth Alliance's ATXS Position: Q1 2023 in Review

Freedom Wealth Alliance sold out of Astria Therapeutics (ATXS) in Q1 2023, closing a stake of 1,150 shares — an estimated $17.1K sold.

Freedom Wealth Alliance first reported a position in ATXS in Q4 2022 and held it in 1 quarter. The position peaked at $17.1K in Q4 2022. 65 funds tracked by Wall St. Rank hold ATXS as of Q1 2023.

  • Freedom Wealth Alliance reported no remaining Astria Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Freedom Wealth Alliance sold 1,150 Astria Therapeutics shares in Q1 2023, an estimated $17.1K.
  • Freedom Wealth Alliance first reported a position in Astria Therapeutics in Q4 2022 and held it in 1 quarter.
  • Freedom Wealth Alliance's Astria Therapeutics position peaked at $17.1K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2023.

Based on Freedom Wealth Alliance's 13F filing for Q1 2023, filed 25 Apr 2023.